Tables of Rules
HIV- 2

Nucleoside and Nucleotide reverse transcriptase inhibitors Protease inhibitors

Non-Nucleoside reverse transcriptase inhibitors Fusion inhibitors

HIV - 2 Integrase inhibitors


NUCLEOSIDE AND NUCLEOTIDE REVERSE TRANSCRIPTASE INHIBITORS


  Mutations associated with resistance Mutations associated with « possible resistance »
ZDV
Q151M
S215A/C/F/L/Y + 1 mutation among K65R, N69S/T, K70R, Y115F, K223R

  S215A/C/F/L/Y
3TC/FTC
M184I/V

K65R
ddI
K65R
L74V
Q151M


d4T
Q151M
S215A/C/F/L/Y + 1 mutation among K65R, N69S/T, K70R, Y115F, K223R

K65R
S215A/C/F/L/Y
ABC
K65R
Q151M
M184I/V + 1 mutation among: L74V, Y115F
2 mutations among: D67N, K70N/R, M184V/I, S215A/C/F/L/Y
TDF
K65R
Q151M + V111I
 
ZDV: zidovudine, 3TC: lamivudine, FTC: emtricitabine, ddI: didanosine, d4T: stavudine, ABC: abacavir, TDF: tenofovir


PROTEASE INHIBITORS

  Mutations associated with resistance Mutations associated with « possible resistance »
SQV

G48V
I54M + I82F
I84V
L90M
I54L/M
LPV
I84V + L90M + 1 mutation among: I54M, I82F
I54M +I82F
V47A
V62A + L99F
1 mutation among: I54M, I82F + 1 mutation among I84V, L90M
DRV I50V + I84V

I50V
I54M
I84V
FPV
Natural resistance
 
ATV Conflicting data, not currently recommended


TPV
Not recommended
 
SQV: saquinavir, , FPV: fosamprenavir, LPV: lopinavir, ATV:atazanavir, TPV: tipranavir, DRV : darunavir


INTEGRASE INHIBITOR

  Mutations associated with resistance Mutations associated with "possible resistance"
RAL
Y143C/G +1 mutation among: E92Q, T97A
Q148K/R
N155H/R

E92Q
Y143C/G
RAL: raltegravir

NON-nuclEosidE REVERSE TRANSCRIPTASE INHIBITORS

Naturally resistant to all NNRTI [2]

FUSION INHIBITOR

Naturally resistant to T20 [2]


References